China Taiping announced 3Q25 financial results for its key operations in mainland China. We highlight that Taiping Life, which contributed to more than 100% of FY24 group profit by our estimates, reported a 379% yoy increase in net profit, driven by equity investment gains and a reduction in effective tax rate (vs. 3Q24). Book value for Taiping Life, increased 15% in 3Q, reflecting both the strong net profit and positive impact from the increase in long-term bond yields. 3Q25 results for Taiping Life was well ahead of our above-consensus expectations, and is likely to lead to large upward revisions to FY25 estimates.
On the other hand, core solvency ratio for Taiping Life declined 38pt in 3Q25 to 156% (from 194% at 2Q25), reflecting drag from further decline in reference liability discount rate (i.e. 750-day average bond yield) and higher minimum capital requirement (due to increase in equity investment allocation).
We update our estimates to reflect 3Q25 results, and raise our FY25 profit/book value estimates by 82%/8% to factor in the strong profit growth at Taiping Life. Our FY26-27 profit/book value estimates are 9-11%/8-9% higher, reflecting the increase in investment portfolio. Our 12-month SOTP-based target price is now HK$15 (vs. HK$13.7 previously), driven mainly by the increase in book value. Maintain Neutral.
Price Target Risks and Methodology - China Taiping Insurance Holdings
We are Neutral rated on China Taiping. Our 12-month, SOTP-based target price is HK$15.0, implying 0.5X FY26E P/B. We value 1) Taiping Life at 0.6X FY25E P/B, based on our ROA projection; and 2) Taiping P&C and Taiping Re at 0.4X/0.4X P/B, based on FY26E ROE of 6.8%/7.0%.
Upside risks: Further improvement in life core solvency capital position and increase in capital upstream to the group, which could allow for higher dividend payout; Reduced capital consumption in the HK life insurance operation; Improvements in operating results in non-insurance segments; Better-than-expected investment results and normalized tax expenses.
Downside risks: Weaker-than-expected investment results to drag profit growth; Inability to maintain new policy sales growth, leading to continued decline in CSM balance and lower-than-expected NBV; Lower dividend payout ratio, reflecting further solvency constraint and profit growth pressure from both life and non-life insurance segments.